285 related articles for article (PubMed ID: 30226786)
1. TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings.
Shetab Boushehri MA; Lamprecht A
Mol Pharm; 2018 Nov; 15(11):4777-4800. PubMed ID: 30226786
[TBL] [Abstract][Full Text] [Related]
2. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents.
Baldridge JR; McGowan P; Evans JT; Cluff C; Mossman S; Johnson D; Persing D
Expert Opin Biol Ther; 2004 Jul; 4(7):1129-38. PubMed ID: 15268679
[TBL] [Abstract][Full Text] [Related]
3. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.
Kuai R; Sun X; Yuan W; Ochyl LJ; Xu Y; Hassani Najafabadi A; Scheetz L; Yu MZ; Balwani I; Schwendeman A; Moon JJ
J Control Release; 2018 Jul; 282():131-139. PubMed ID: 29702142
[TBL] [Abstract][Full Text] [Related]
4. Cancer Immunotherapy of TLR4 Agonist-Antigen Constructs Enhanced with Pathogen-Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD-L1.
Traini G; Ruiz-de-Angulo A; Blanco-Canosa JB; Zamacola Bascarán K; Molinaro A; Silipo A; Escors D; Mareque-Rivas JC
Small; 2019 Jan; 15(4):e1803993. PubMed ID: 30569516
[TBL] [Abstract][Full Text] [Related]
5. TLR4 agonists as immunomodulatory agents.
Alderson MR; McGowan P; Baldridge JR; Probst P
J Endotoxin Res; 2006; 12(5):313-9. PubMed ID: 17059695
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 4 activation in cancer progression and therapy.
Oblak A; Jerala R
Clin Dev Immunol; 2011; 2011():609579. PubMed ID: 22110526
[TBL] [Abstract][Full Text] [Related]
7. TLR4- and TLR9-dependent effects on cytokines, cell viability, and invasion in human bladder cancer cells.
Olbert PJ; Kesch C; Henrici M; Subtil FS; Honacker A; Hegele A; Hofmann R; Hänze J
Urol Oncol; 2015 Mar; 33(3):110.e19-27. PubMed ID: 25499923
[TBL] [Abstract][Full Text] [Related]
8. Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics.
Johnson DA
Curr Top Med Chem; 2008; 8(2):64-79. PubMed ID: 18289078
[TBL] [Abstract][Full Text] [Related]
9. TLR8 combined withTLR3 or TLR4 agonists enhances DC-NK driven effector Tc1 cells.
Nouri-Shirazi M; Tamjidi S; Nourishirazi E; Guinet E
Immunol Lett; 2018 Jan; 193():58-66. PubMed ID: 29103998
[TBL] [Abstract][Full Text] [Related]
10. Use of adjuvants for immunotherapy.
Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists.
Peri F; Piazza M
Biotechnol Adv; 2012; 30(1):251-60. PubMed ID: 21664961
[TBL] [Abstract][Full Text] [Related]
12. Molecular simplification of lipid A structure: TLR4-modulating cationic and anionic amphiphiles.
Calabrese V; Cighetti R; Peri F
Mol Immunol; 2015 Feb; 63(2):153-61. PubMed ID: 24939379
[TBL] [Abstract][Full Text] [Related]
13. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants.
Reed SG; Hsu FC; Carter D; Orr MT
Curr Opin Immunol; 2016 Aug; 41():85-90. PubMed ID: 27392183
[TBL] [Abstract][Full Text] [Related]
14. Immunobiology and application of toll-like receptor 4 agonists to augment host resistance to infection.
Hernandez A; Patil NK; Stothers CL; Luan L; McBride MA; Owen AM; Burelbach KR; Williams DL; Sherwood ER; Bohannon JK
Pharmacol Res; 2019 Dec; 150():104502. PubMed ID: 31689522
[TBL] [Abstract][Full Text] [Related]
15. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.
Garay RP; Viens P; Bauer J; Normier G; Bardou M; Jeannin JF; Chiavaroli C
Eur J Pharmacol; 2007 Jun; 563(1-3):1-17. PubMed ID: 17383632
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
18. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
Mata-Haro V; Cekic C; Martin M; Chilton PM; Casella CR; Mitchell TC
Science; 2007 Jun; 316(5831):1628-32. PubMed ID: 17569868
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine's anti-tumor actions may depend on the mitotic apoptosis, autophagy and inflammation: hypotheses with implications for chemo-immunotherapy of advanced cancers and pediatric gliomas.
Altinoz MA; Ozpinar A; Alturfan EE; Elmaci I
J Chemother; 2018 Jul; 30(4):203-212. PubMed ID: 30025492
[TBL] [Abstract][Full Text] [Related]
20. Increasing the Chemical Variety of Small-Molecule-Based TLR4 Modulators: An Overview.
Romerio A; Peri F
Front Immunol; 2020; 11():1210. PubMed ID: 32765484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
